Investor Presentation - First Six Months of 2021
53
Investor presentation
First six months of 2021
Novo Nordisk®
People with obesity are at an increased risk of developing severe
comorbidities that are life-threatening and costly for society
Diabetes Increased risk of type 2 diabetes
Only 2% of the 650 million people with obesity are
treated with prescription medication
Global healthcare cost related to obesity
expected to increase by 20% by 2025
CVD
Increased risk of CVD
650 million
people with
obesity
Heart
failure
Increased risk of heart failure
Sleep
apnoea
Increased severity of sleep apnoea
Visit the
doctor
Osteo-
arthritis
Increased risk of osteoarthritis
CVD: Cardiovascular disease; AOM: Anti-obesity medication, TRX SU Volume.
The figure illustrates some of the intervention points to treat obesity with prescription medication
1 Attempt to manage weight through lifestyle modification or surgery
22% of people with obesity are estimated to be treated with anti-obesity medication
Source: World Obesity Federation, 2017
Discussion and
evaluation of
next steps Actively
+20%
USD
~1.0 trillion
USD
~1.2 trillion
managed 2% treated²
2020
2025View entire presentation